2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11B.06 The Impact of Body Mass Index on Immune-Related Adverse Events and Outcomes in Patients with Lung Cancer: A Real-World Study

EP.11B.06 The Impact of Body Mass Index on Immune-Related Adverse Events and Outcomes in Patients with Lung Cancer: A Real-World Study

Back to course

Pdf Summary

The study explored the relationship between body mass index (BMI) and immune-related adverse events (irAEs) in lung cancer patients treated with immune checkpoint inhibitors (ICIs). The research, conducted at Tufts Medical Center, analyzed data from 125 lung cancer patients who began ICI treatment between 2018 and 2021. Patients were categorized into high BMI (≥25 kg/m²) and low BMI (<25 kg/m²) groups. <br /><br />Key findings indicate that BMI did not significantly correlate with the overall occurrence of irAEs, such as pneumonitis. However, overweight or obese patients (high BMI) showed a slight propensity toward developing endocrinopathies. Despite these adverse events, BMI did not impact the efficacy of ICIs in terms of progression-free survival (PFS) and overall survival (OS) in advanced-stage lung cancer patients.<br /><br />High BMI groups were predominantly White, with fewer prior infections before treatment commencement. Most of the patients suffered from advanced-stage non-small cell lung cancer, and Pembrolizumab was the most prevalent ICI used.<br /><br />Methodologically, logistic regression assessed the BMI-irAE relationship, while the log-rank test and Cox regression evaluated its impact on patient survival outcomes. The study suggests that while there are minor trends regarding ICI treatment efficacy and BMI, further investigation with larger cohorts is warranted to validate these preliminary findings.

Asset Subtitle

Xiao Hu

Meta Tag

Speaker Xiao Hu

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

body mass index

immune-related adverse events

lung cancer

immune checkpoint inhibitors

Tufts Medical Center

endocrinopathies

progression-free survival

overall survival

Pembrolizumab

logistic regression